Gutscheinbedingungen

*Gültig bis 05.07.2026 auf (fast) alles. Ausgeschlossen sind Smartboxen, Zeitschriften, Tickets, Lebensmittel, Gaming-Elektroartikel, Tinte/Toner, Gutscheine, Geschenkkarten, Blumen und Abos | Einlösbar in allen Buchhandlungen von Orell Füssli, Barth Bücher, Buchladen Rapunzel, Papeterie Köhler, Schuler Orell Füssli, Stauffacher und ZAP unter Vorweisung des Gutscheins, auf www.orellfüssli.ch durch Eingabe des Gutscheincodes. Beim Service „eBooks verschenken“ und bei eBook-Käufen via eReader nicht einlösbar | Mindesteinkaufswert: Fr. 30.- | Nicht mit anderen Rabatten kumulierbar.

Produktbild: Cardiovascular Considerations in Hematopoietic Stem Cell Transplantation

Cardiovascular Considerations in Hematopoietic Stem Cell Transplantation

Fr. 137.00

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

08.05.2025

Herausgeber

Azin Alizadehasl + weitere

Verlag

Springer

Seitenzahl

291

Maße (L/B/H)

23.5/15.5/1.2 cm

Gewicht

513 g

Sprache

Englisch

ISBN

978-3-031-53661-8

Beschreibung

Portrait



Dr. Azin Alizadehasl, a cardio-oncologist and echocardiologist, stands as the head and founder of the first cardio-oncology ward and research center at Rajaei Heart Institute in Iran. Currently serving as the assistant professor at Rajaei Heart Institute, she embarked on her medical degree as the first rank student and expanding her knowledge through diverse courses in the USA and Canada, Dr. Alizadehasl has achieved noteworthy distinctions, including the Fellowship of the American Society of Echocardiography (FASE) and the Fellowship of the American College of Cardiology (FACC).

Professor Ardeshir Ghavamzadeh is widely recognized as the pioneer of hemato-oncology in Iran. He holds the distinction of being the first individual to perform a Bone Marrow Transplant (BMT) in the country. In recognition of his exceptional contributions, he was honored with the prestigious CIBMTR Distinguished Service Award in 2012.

Dr. Amirhossein Emami is an assistant professor of hemato-oncology at Tehran University of Medical Sciences, currently he is the head of hemato-oncology and stem cell transplantation ward of Imam Khomeini Hospital of Tehran. He has previously held the position of head of Tehran Medical School. He was bestowed with the prestigious "Medical Education Award" in 2011. His primary area of expertise revolves around advancing oncology care by fostering the growth of multi-disciplinary teams, with a specific focus on colorectal malignancies

Dr. Ghasem Janbabaei is a hemato-oncologist at Tehran University of Medical Science. He has achieved the 3rd rank in the board certification of Internal Medicine in Iran. He has previously served as the head of the Deputy of Medical Affairs at the Ministry of Health in Iran and has authored approximately 200 articles in the field of oncology.

Dr. Davood Khoda-Amorzideh is a cardiologist and the first graduate of the cardio-oncology fellowship in Iran. He has published numerous books in the field of cardiology, including translations of reference books in Persian for medical doctors. Additionally, he has authored several articles in the field of cardio-oncology. Currently, he is actively involved in the treatment of cardiac complications in cancer patients in Tehran.

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

08.05.2025

Herausgeber

Verlag

Springer

Seitenzahl

291

Maße (L/B/H)

23.5/15.5/1.2 cm

Gewicht

513 g

Sprache

Englisch

ISBN

978-3-031-53661-8

Herstelleradresse

Springer-Verlag GmbH
Tiergartenstr. 17
69121 Heidelberg
DE

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

  • Produktbild: Cardiovascular Considerations in Hematopoietic Stem Cell Transplantation
  • HSCT at a glance.- Burden of cardiovascular disease in HSCT.- Risk factors and Mechanisms of Cardiotoxicity in HSCT.- Cardiotoxicity of commonly used drugs in HSCT.- Pre-HSCT cardiovascular evaluation.- HSCT in low EF patients.- Arrhythmias and conduction disorders in HSCT.- Coronary and peripheral arterial disease in HSCT.- Thrombotic disease in HSCT.- Pulmonary hypertension in HSCT.- Pericardial disease in HSCT.- Metabolic syndrome in HSCT.- HSCT in patients with cardiac amyloidosis.- HSCT in patients with autoimmune conditions, sickle cell anaemia and thalassemia.- Cardiotoxicity surveillance and cardioprotective strategies in HSCT.